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Background: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) show beneficial effects on cardiovascular health
and cognitive functions, but the underlying molecular mechanisms are not completely understood. Because of the
fact that cytoskeleton dynamics affect almost every cellular process, the regulation of cytoskeletal dynamics could
be a new pathway by which n-3 PUFAs exert their effects on cellular level.
Methods: A 12-week open-label intervention study with 12 healthy men was conducted to determine the effects
of 2.7 g/d n-3 PUFA on changes in mRNA expression of cytoskeleton-associated genes by quantitative real-time
PCR in whole blood. Furthermore, the actin content in red blood cells was analyzed by immunofluorescence
imaging.
Results: N-3 PUFA supplementation resulted in a significant down-regulation of cytoskeleton-associated genes, in
particular three GTPases (RAC1, RHOA, CDC42), three kinases (ROCK1, PAK2, LIMK), two Wiskott-Aldrich syndrome
proteins (WASL, WASF2) as well as actin related protein 2/3 complex (ARPC2, ARPC3) and cofilin (CFL1). Variability
in F-actin content between subjects was high; reduced actin content was only reduced within group evaluation.
Conclusions: Reduced cytoskeleton-associated gene expression after n-3 PUFA supplementation suggests that
regulation of cytoskeleton dynamics might be an additional way by which n-3 PUFAs exert their cellular effects.
Concerning F-actin, this analysis did not reveal unmistakable results impeding a generalized conclusion.
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Fish oil and its principal omega-3 polyunsaturated fatty
acids (n-3 PUFAs), eicosapentaenoic acid (EPA) and doc-
osahexaenoic acid (DHA), have shown beneficial effects
in the prevention of atherosclerosis and cardiovascular
diseases [1,2]. They are incorporated into cell membranes
and show potent anti-inflammatory, anti-thrombotic, anti-
arrhythmic, and triacylglycerol-lowering activities [3-5]. In
addition, indications for the neuroprotective functions of
n-3 PUFAs have been constantly increased in the last few
years, including effects on learning memory and preven-
tion of neurodegenerative diseases by the deceleration of
cognitive decline [6,7]. However, the underlying molecular
mechanisms by which n-3 PUFAs exert their effects are
versatile and not completely understood. The modulation
of membrane micro-organization and the regulation of* Correspondence: hahn@nutrition.uni-hannover.de
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unless otherwise stated.gene expression are believed to be key mechanisms by
which n-3 PUFAs mediate their functions [8]. The regu-
lation of gene expression via nuclear receptors and tran-
scription factors enables n-3 PUFAs and their bioactive
metabolites to affect a myriad of molecular pathways. In
a recent study investigating the effect of n-3 PUFA on
the whole genome expression in humans [9-11], we ob-
served significant changes in the expression of several
cytoskeleton-associated genes [GSE34898] after a twelve
week supplementation with fish oil (1.56 g EPA and
1.14 g DHA) or placebo (corn oil) in n = 20 normolipide-
mic (see Additional file 1: Table S1) and in n = 20 dyslipid-
emic subjects (see Additional file 1: Table S2). Independent
of the oil, a significantly higher number of genes was regu-
lated in dyslipidemic subjects compared to normolipidemic
subjects. Gene lists show regulated genes coding for struc-
tural components of the cytoskeleton (actinin, moesin),
muscles (dystrophin, myosin) as well as for several factors
which are responsible for the regulation of cytoskeletonl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Anthropometric data, lipid levels and fatty acid
content in red blood cell membranes measurements
Parameters t0 t12
Age [years] 43.33 ± 4.40
Height [cm] 183.04 ± 1.32
Weight [kg] 87.88 ± 10.60 89.25 ± 10.92
Body mass index [kg/m2] 26.17 ± 2.31 26.57 ± 2.37
Waist circumference [cm] 92.25 ± 8.31 93.67 ± 10.15
Hip circumference [cm] 102.17 ± 6.34 103.50 ± 7.30
Lipid levels
Total cholesterol [mg/dl] 217.42 ± 59.14 226.33 ± 53.44
Triacylglycerol [mg/dl] 146.25 ± 63.37 109.92 ± 32.88a)
High-density lipoprotein cholesterol
[mg/dl]
52.00 ± 11.35 54.33 ± 8.48
Low-density lipoprotein cholesterol
[mg/dl]
144.83 ± 50.49 155.33 ± 46.37
LDL/HDL ratio 2.91 ± 1.09 2.94 ± 1.06
Fatty acids
Omega-6 series:
Dihomo-γ-linolenic acid (20:3 n6)
[% of total fatty acids]
2.04 ± 0.56 1.44 ± 0.34a)
Arachidonic acid (20:4 n6) [% of
total fatty acids]
15.62 ± 0.87 12.26 ± 1.46a)
Adrenic acid (22:4 n6) [% of total
fatty acids]
3.21 ± 0.56 1.88 ± 0.35a)
Docosapentaenoic acid (22:5 n6)
[% of total fatty acids]
0.72 ± 0.11 0.45 ± 0.08a)
Omega-3 series:
Eicosapentaenoic acid (22:5 n3)
[% of total fatty acids]
0.92 ± 0.21 3.76 ± 0.84a)
Docosapentaenoic acid (20:5 n3)
[% of total fatty acids]
2.92 ± 0.20 3.67 ± 0.43a)
Docosahexaenoic acid (22:6 n3)
[% of total fatty acids]
4.83 ± 1.20 7.15 ± 0.79a)
Omega-3 index [% of total
fatty acids]
5.74 ± 1.37 10.91 ± 1.53a)
Results are presented as mean ± SD.
a)t0 values vs. t12 values of subjects were tested by paired student’s
t-test; p < 0.05.
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(syndecan) and actin remodeling (Arp 2/3 complex, CapZ
beta, WASP). These regulations could be another pathway
by which n-3 PUFAs mediate their effects.
The cytoskeleton is an extensive framework of protein
fibers in the cytoplasm. There are three main types of
cytoskeletal polymers: actin filaments, microtubules and
intermediate filaments which influence various mechan-
ical and chemical stimuli within and between cells as
well as subcellular structures [12,13]. Changes of length,
concentration and attachments to each other or to the
cell membrane of these filaments are essential processes
for all biological functions [14]. Therefore, cytoskeleton
dynamics affect almost every cell-biological process, such
as growth, differentiation, division, and death, but are also
responsible for cell shape and distribution, inter- and
intracellular transport and signaling, motility and adhesion
[15]. Several diseases such as cardiovascular and neuro-
degenerative diseases, the immunodeficiency syndrome,
Wiskott - Aldrich syndrome (WAS), cancer or liver cir-
rhosis have now been associated with abnormalities in
cytoskeleton proteins [16]. To better understand the
effect of n-3 PUFAs on cytoskeletal assembly, we con-
ducted an open-label intervention study with healthy
middle-aged men to investigate the gene expression
changes of cytoskeletal genes as well as the alterations
in actin dynamics after n-3 PUFA supplementation.
Results
Subject characteristics and changes of lipid levels, fatty
acid composition of red blood cell membranes and
omega-3 index
All subjects completed the study and tolerated the treat-
ment with fish oil capsules very well. Compliance of
subjects was determined by the counting of remaining
capsules as well as by the omega-3 index. The mean age
of all participating subjects was 43.3 ± 4.4 years. After n-3
PUFA supplementation the triacylglycerol levels signifi-
cantly decreased by 24.8% (Table 1). Furthermore, relative
amounts of n-6 PUFA levels in the red blood cell mem-
branes were reduced, while n-3 PUFA levels increased. In
contrast, relative EPA and DHA levels increased, which is
reflected by a significant increase of the omega-3 index by
47% (Table 1).
Gene expression changes of cytoskeleton-associated
genes after n-3 PUFA supplementation
The gene expression of three GTPases (ras-related C3
botulinum toxin substrate 1 (RAC1), ras homolog family
member A (RHOA), cell division cycle 42RAC1 (CDC42)),
three kinases (Rho-associated coiled-coil containing protein
kinase 1 (ROCK1), p21 protein-activated kinase 2 (PAK2),
LIM domain kinase 2 (LIMK2)), two Wiskott-Aldrich syn-
drome proteins (Wiskott-Aldrich syndrome-like (WASL),WAS protein family, member 2 (WASF2)), actin-related
protein 2/3 complex (ARPC2, ARPC3), and cofilin (CFL1)
were significantly down-regulated after n-3 PUFA supple-
mentation (Figure 1). The strongest down-regulation was
observed in WASL (−2.02) and ARPC3 (−2.21).Changes of F-actin content in red blood cells
The total fluorescence intensity of phalloidin-labelled
F-actin in red blood cells was quantified at baseline and
after twelve weeks of supplementation with n-3 PUFAs
(Table 2). Of the twelve subjects, one half showed an in-
crease and the other half a decrease in total fluorescence
Figure 1 Expression changes of cytoskeleton-associated target genes in healthy men after n-3 PUFA supplementation. Transcript levels
of RHOA, CDC42, RAC1, PAK2, ROCK1, LIMK2, WASL, WASF2, BAIAP2, ARPC2, ARPC3, and CFL1 were determined by qRT-PCR in healthy middle-aged
men before (t0) and after 12 weeks (t12) of 2.7 g/d n-3 PUFA supplementation. Each sample was used in triplicate. Triplicates were averaged and
corrected by two reference genes (GAPDH and RPS2). Corrected expressions of all subjects were compared with the baseline gene expression
and the relative expression changes are displayed. Differences between time points were tested by Wilcoxon test. Asterisks mark the following
significance levels: *p < 0.05; **p < 0.01.
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Whole group analysis revealed a significant decrease of
phalloidin-labeled F-actin by 9.72% after n-3 PUFA
supplementation. Figure 2 shows examples of decreased
and increased fluorescence intensity after n-3 PUFA
supplementation. Although no significant correlationTable 2 Fluorescence intensity of phalloidin-labeled filamento
Fluorescence intensity of whole cell
Subject t0 t12
1 60.17 ± 18.78 65.68 ± 7
2 84.25 ± 4.92 37.91 ± 7
3 52.12 ± 19.86 61.71 ± 1
4 39.93 ± 8.47 30.15 ± 8
5 25.61 ± 8.35 37.76 ± 9
6 52.02 ± 13.51 64.95 ± 4
7 31.89 ± 8.27 23.47 ± 7
8 36.11 ± 14.67 47.56 ± 2
9 42.87 ± 18.46 58.42 ± 1
10 67.53 ± 6.09 46.77 ± 1
11 66.88 ± 9.87 62.84 ± 1
12 59.17 ± 5.32 21.24 ± 1
t0 t12
Group averageb) 51.55 ± 20.28 46.54 ± 1
Ten images were taken of each subject sample (n = 12) at each time point. Therefo
analyzed by Fiji software package [30]. Firstly, all images were calibrated for intensi
optimal threshold was selected by multiple testing and applied to all images (selec
of phalloidin-labeled filamentous actin in each cell was measured. Results are prese
a)t0 values vs. t12 values of subjects were tested by paired student’s t-test.
b)n = 120.between fatty acid composition and F-actin content could
be investigated, a weak negative correlation (r = −0.397;
p = 0.055) between the percentage DHA amount and
F-actin content could be observed.
A bivariate Pearson’s correlation analysis between
baseline fluorescence intensity and changes of intensityus actin in red blood cells
p-valuesa) Difference (t12 – t0)
.93 0.401 5.52










1.67 < 0.001 −37.94
9.67 0.040 −5.01
re, a total of 240 images (120 cells at each time point (t0 and t12)) were
ty ranges. Secondly, all images were filtered by a 2 μm median filter. An
ted threshold: Li). After this post-processing, the overall fluorescence intensity
nted as mean ± SD. Statistically significant differences are marked in bold.
Figure 2 N-3 PUFA induced changes in filamentous actin content in red blood cells. Filamentous actin in red blood cells of healthy
middle-aged men before (t0) and after 12 weeks (t12) of 2.7 g/d n-3 PUFA supplementation were labeled with phalloidin and whole cell fluorescence
intensity was determined by confocal laser microscopy and data processing. The figure show examples for n-3 PUFA supplementation induced
fluorescence intensity changes of two subjects. An increase (A) or a decrease (B) of phalloidin-labeled F-actin in red blood cells from baseline
(t0) to study completion (t12) is shown.
Schmidt et al. Lipids in Health and Disease 2015, 14:4 Page 4 of 9
http://www.lipidworld.com/content/14/1/4(Δt12 - t0) revealed that the higher the baseline intensity
was, the stronger F-actin decreased during intervention.
The correlation coefficient was r = −0.641 (p < 0.05).
Discussion
Incorporation of n-3 PUFA in cell membranes affects a
wide spectrum of cellular activities, including the actin
cytoskeleton [17]. The influence of n-3 PUFA on cytoskel-
eton dynamics may prove a novel pathway for n-3 PUFA
actions. The actin cytoskeleton plays an important role in
various processes accompanied with the organization,
formation and connection of cellular structures [13,18].
Thus, changes of the regulation or function of cytoskeletal
organization can contribute to diseases such as neuro-
logical disorders, CVD, WAS, or cancer [18]. In a previous
whole genome gene expression study with humans [9-11],
we found an altered regulation of the expression of several
cytoskeleton-associated genes [GSE34898] in response to
n-3 PUFAs treatment. In order to discover the possible
influence of n-3 PUFAs on cytoskeleton assembly, we con-
ducted another intervention study with healthy middle-
aged men and investigated the effects of n-3 PUFA
supplementation on the expression of related genes aswell as alterations in actin dynamics. To the best of our
knowledge, this is the first human study analyzing n-3
PUFA-induced gene expression changes as well as the dif-
ferences of F-actin content in red blood cells.
Gene expression analysis of cytoskeleton-associated genes
revealed a down-regulation of GTPases (RAC1, RHOA,
CDC42), kinases (ROCK1, PAK1, LIMK), Wiskott-Aldrich
syndrome proteins (WASL, WASF2), actin-related pro-
tein 2/3 complex (ARPC2, ARPC3), and cofilin 1 (CFL1)
after n-3 PUFA supplementation (Figure 1), suggesting
that n-3 PUFAs influence the actin cytoskeleton in
healthy men.
Comparable data of gene expression changes are avail-
able only from a limited number of animal [19-22] and
in vitro studies ([23,24] abstract only). In these studies, n-3
PUFA supplementation resulted in an up-regulation of
actin-related protein-2 in rat brains [19] as well as WASL
in the precentral gyrus of the cerebral cortex of baboon ne-
onates after a low (0.33 w/w% DHA) or high (1.00 w/w%
DHA) PUFA diet for 12 weeks [21], respectively. In con-
trast, incubation of prostate cancer cells with EPA and
DHA reduced the protein expression of GTPases (rac1,
rac2 and cdc42) [24 (abstract only)].
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fluorescence analysis of phalloidin-labeled F-actin in red
blood cells showed a significant F-actin reduction of
9.72% but only for group evaluation (Table 2). In fact, vari-
ability in F-actin content between subjects was high and
showed little marked direction. Hence, these data do not
convey a clear picture impeding a generalized conclusion.
Probably, baseline levels of intensity might have a relevant
influence on F-actin changes. Here, we have seen more
pronounced changes of immunofluorescence intensity
when the baseline F-actin in red blood cells was higher.
On individual level, no clear differences in the baseline
characteristics of the subjects were observed. It should
also be noted that high variations results from interindi-
vidual but also analytical variability.
A reduction of F-actin content in red blood cells has
also been shown after n-3 PUFA incubation (50 μM for
48 h) of human trabecular meshwork cells which re-
sulted in changes of the F-actin cytoskeleton, in particu-
lar, prevention of oxidative stress-induced (1 h 300 μM
hydrogen peroxide) stress fibers and cross-linked actin
network formation [25]. In addition, n-3 ethyl ester in-
cubation in murine heart endothelial cells leads to a re-
duced migration of cells into induced wounds as well as
a changed assembly of actin filament and focal adhesion
in migrating and non-contacting cells [26]. Sakamoto
and co-workers determined increased F-actin protein
expression in the hippocampus of adult mice by 60%
after supplementation with 300 mg/kg DHA for four
weeks [27].
However, an increase or decrease of F-actin does not
necessarily imply an advance or decline in function. Ra-
ther, an architectural and ultra-structural reorganization
is to be expected.
Expression changes of cytoskeletal genes as well as chan-
ged F-actin content investigated in animal and in vitro
studies are only partially transferable to the expression and
F-actin changes observed in the current study, which are
mainly attributable to analyzing different species and
compartments. The results of the expression changes of
cytoskeleton-associated genes and altered F-actin content
of red blood cells after n-3 PUFA supplementation in this
study are inconsistent. We cannot clearly indicate that n-3
PUFAs influence the actin cytoskeleton assembly by the
regulation of cytoskeletal gene expression in healthy sub-
jects. One can speculate that the organization of the actin
cytoskeleton might be induced by n-3 PUFA supplementa-
tion, which consequently modifies cellular signaling [28].
Further studies are required to clarify mechanisms by
which n-3 PUFA influence membrane micro-organization
and modulate biological responses. Additionally, other
polymers and actin isoforms which might be linked to dis-
ease and cytoskeletal organization as well as degeneration
must be taken into account.The study has a number of potential limitations. Al-
though, n-3 PUFAs appear to regulate cytoskeleton-
associated gene expression and change F-actin content in
red blood cells, it is uncertain whether this would result in
cellular consequences. This is mainly due to the fact that
cytoskeleton markers, especially Rho-GTPases, are tightly
regulated and post-translational modified, which finally
determine their localization and function. Therefore, fur-
ther studies analyzing cytoskeleton markers on protein
level and cellular processes (i.e. cell division) in model
systems are needed to verify the results and transfer it to
cellular consequences.
Conclusions
In conclusion, n-3 PUFA supplementation induced ex-
pression changes of cytoskeleton-associated genes on a
transcriptional level in blood cells indicating that n-3
PUFAs influence the actin cytoskeleton. However, the in-
terindividual variance in the F-actin content in red blood
cells was high, which might mask effects of n-3 PUFA.
Methods
This controlled explorative intervention study was con-
ducted at the Institute of Food Science and Human
Nutrition, Leibniz University of Hannover, Germany,
and performed with respect to Good Clinical Practice
Guidelines. The approval of the Freiburg Ethics Commis-
sion International (feki Code: 012/1707) was received.
Subjects
Twelve healthy men aged between 36 and 49 years were
recruited. The suitability of volunteers was checked by de-
termination of blood parameters and by an admission
questionnaire on diet, lifestyle and diseases. Exclusion cri-
teria were defined as: smoking; body mass index > 35 kg/
m2; chronic cardiovascular or liver diseases; gastrointes-
tinal disorders; blood coagulation disorders and intake of
coagulation-inhibiting drugs; renal failure; intake of any
corticosteroids, lipid-lowering or anti-inflammatory drugs;
periodic intake of laxatives; regular use of dietary supple-
ments containing n-3 PUFA, phytosterols, polyglucosa-
mines, and other lipid-binding ingredients or daily eating
of fatty fish; allergy to fish or fish oil; and participation in
another clinical study < 30 days before the study start or at
the same time. Written informed consent was obtained
from all participants.
Study design
Subjects ingested six fish oil capsules per day for a period
of twelve weeks. The daily intake of n-3 PUFA was 2.7 g
(1.56 g EPA and 1.14 g DHA). The subjects were instructed
to take three capsules in the morning and three in the
evening together with food and a glass of water. Usual ex-
ercise and dietary habits should be maintained throughout
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a questionnaire to obtain information about changes in
medication, diet (e.g. changes in weekly fish intake, pre-
ferred fish dishes or species, respectively) and lifestyle
habits (e.g. physical activity), as well as tolerability to
the capsules.
Determination of fasting serum lipids
Fasting venous blood samples were collected in BD
Vacutainer® Blood Collection Tubes (Becton Dickinson,
Heidelberg, Germany) at baseline and after twelve weeks
of supplementation. The plasma lipid levels were deter-
mined by specific enzymatic color reactions from an ex-
ternal contract laboratory (LADR, Hannover, Germany).
The results are presented as mean ± SD (Table 1).
Determination of red blood cell membrane fatty acid
composition
In order to determine the relative fatty acid composition
in red blood cell membranes, samples were centrifuged
at 2000 g for 10 min. Red blood cell concentrate was
transferred to a new tube and stored at −80°C until ana-
lysis. Red blood cell membrane fatty acid composition
including the omega-3 index, given as EPA and DHA,
was analyzed at baseline and after twelve weeks of sup-
plementation according to the omega-3 index method-
ology [29]. Results are presented as mean percentage of
the total fatty acids ± SD (Table 1). The coefficient of
variation for EPA and DHA was 5%. Quality was assured
according to DIN ISO 15189.
Determination of F-actin content in red blood cells by
confocal laser scanning fluorescence microscopy
In order to obtain immunofluorescence imaging, the blood
samples were centrifuged at 1200 g for 5 min, red blood
cell concentrate was transferred to a new tube and mixed
with equal amounts of 100% glycerol. Samples were frozen
and stored at −80°C following the high-glycerol/slow-freeze
method until analysis. Red blood cell concentrate-glycerol
mixture was thawed at 37°C in a water bath. An amount of
10 μl of thawed sample was transferred to adhesion slides
(Dianova GmbH, Hamburg, Germany). A second slide was
arranged at an angle of 30° to disperse the blood over the
slide’s length. The blood film was incubated for 30 min in a
wet chamber to facilitate the adhesion of red blood cells to
the slides. After adhesion, the cells were fixed with 200 μl
of 4% methanol-free formaldehyde (Thermo Scientific,
Rockford, USA) within 15 min. Permeabilization and stain-
ing were performed in one step using 100 μl of staining
buffer containing 1xPBS, 0.1% Triton-X (Sigma-Aldrich,
Hamburg, Germany) and 5 μl Alexa Fluor 488 Phalloidin
(New England Biolabs GmbH, Frankfurt, Germany). The
slides were incubated for 30 min in a dark wet chamber.
Subsequently, the slide was dried by gentle patting on anabsorbent cloth. An amount of 10 μl of ProLong Gold
Antifade reagent (New England Biolabs GmbH, Frankfurt,
Germany) was pipetted onto the slide and covered by an
ethanol-cleaned cover slip to seal it. After a 20 min drying
period in the dark, all sides of the slide were sealed with
clear nail polish. The slides were stored in the dark at 4°C
until microscopy.
Confocal laser scanning microscopy was performed
with a Leica Upright DM-R connected to a TCS SP2
AOBS scan head. Alexa Fluor 488 excited at 495 nm and
was visualized between 500 and 545 nm with a band pass
filter. Images were recorded as a matrix of 256 × 256 pixels.
Ten images were taken of each sample with a 100× plan-
apochromat 1.46 oil immersion objective (Nikon, numer-
ical aperture 1.46). A total of 240 images (120 cells at each
time point) were analyzed by the Fiji software package [30].
Firstly, all images were calibrated for intensity ranges.
Secondly, all images were filtered by a 2 μm median filter.
An optimal threshold was selected by multiple testing and
applied to all images. After this post-processing, the overall
intensity of phalloidin-labeled F-actin in each cell was mea-
sured. Results are presented as mean ± SD (Table 2).
Gene expression analyses
Fasting venous blood samples were collected in PAX-
gene Blood RNA Tubes (PreAnalytiX, Hombrechtikon,
Switzerland) at baseline and after twelve weeks of sup-
plementation. Samples were incubated for 24 h in the
PAXgene Blood RNA Tubes at room temperature and
then stored at −20°C until RNA isolation.
The total RNA was isolated with the PAXgene Blood
RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland),
according to the manufacturer’s recommended proce-
dures. The RNA yield was quantified by a Nanodrop ND-
1000 spectrophotometer (peQLab Biotechnologie GmbH,
Erlangen, Germany) measurement. The quality of purified
RNA was checked with an Agilent 2100 Bioanalyzer
using RNA 6000 Nano Chips and a RNA 6000 Nano Kit
(Agilent Technologies, Böblingen, Germany). Only RNA
samples with an optical density 260/280 ratio of more
than 1.8 were used for further analyses.
cDNA from each subject was synthesized twice using
1.0 μg of purified RNA and M-MLV reverse transcript-
ase (Promega, Mannheim, Germany), as well as random
hexamer (Fermentas, St. Leon-Rot, Germany) and oligo
(dT) primers (Carl Roth, Karlsruhe, Germany). Synthe-
sized cDNA was diluted 1:12 with nuclease-free water
and used for the quantitative real-time polymerase chain
reaction (qRT-PCR) together with iQ SYBR Green Super-
mix (Bio-Rad Laboratories, Hercules, Ca, USA) and 5 pmol
of both forward and reverse primers. The sequences for
target and reference genes were retrieved from GenBank
and the primers applied were manually designed with
the Primer-BLAST tool of the National Centre for
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gram Primer 3 [31]. The primer sequences used are
listed in Table 3. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and ribosomal protein S2 (RPS2) were
identified as the most stable reference genes by the
freely available algorithm geNorm version 3.5.
Relative expression ratios of genes, which were quanti-
fied by qRT-PCR, were calculated with the Gene Expres-
sion Macro tool of Bio-Rad, which is based on the
algorithm of geNorm [32]. Firstly, normalization factors
were calculated from the geometric mean of the refer-
ence genes GAPDH and RPS2. Furthermore, the base-
























Reference genes GAPDH NM_00204
RPS2 NM_00295expression values could be calculated. Therefore, the
baseline samples are given a value of 1. The results are
presented as relative expression values ± SE (Figure 1).
Statistics
All datasets were tested for distribution and homogen-
eity of variance before statistical analysis. Differences
between time points were tested by paired student’s
t-test (normal distribution) or Wilcoxon test for data-
sets which were not normally distributed. Correlation
coefficient was determined with Pearson’s correlation.
In general, p-values ≤ 0.05 were interpreted as statisti-
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software version 21.0 (SPSS Inc., Chicago, IL, USA).
Statistical analysis of expression and immunofluores-
cence data were analyzed using the statistical package R
version 2.15.0.
Additional file
Additional file 1: Brief summary of previous findings. The two
supplementary tables illustrate a selected number of regulated genes
associated with cytoskeleton structure and/or function in normolipidemic
(Table S1) and dyslipidemic subjects (Table S2).
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